Whereas the majority of VavP-BCL2;Ezh2Y641F and 20% of VavP-BCL2;Ezh2wt bone marrow chimeras developed lymphoma displaying morphological features of DLBCL with hepatosplenomegaly on day 111, none of the VavP-BCL2 chimeras displayed overt lymphoma manifestation at that stage (55). This evidence concerns the gene BCL2 and lymphoma.